Results 31 to 40 of about 5,957,667 (290)

Radioiodine and thyroid eye disease [PDF]

open access: yesBMJ, 1999
Ophthalmopathy is a characteristic feature of Graves' disease, although it is usually mild or subclinical. Enlargement of the extraocular muscle can be shown by computed tomography or magnetic resonance scanning in most patients with autoimmune hyperthyroidism, but only in 10-25% of cases does this result in clinically important problems such as ...
Walsh, JP, Dayan, CM, Potts, MJ
openaire   +4 more sources

Tocilizumab for thyroid eye disease [PDF]

open access: yesCochrane Database of Systematic Reviews, 2018
Thyroid eye disease (TED) is an autoimmune disorder that constitutes a major clinical and therapeutic challenge. Current treatment options for moderate-to-severe TED include immunotherapy, orbital radiotherapy and decompression surgery. Limited drugs of proven efficacy are available for the treatment of people with TED.
Shirin, Hamed Azzam   +3 more
openaire   +3 more sources

Teprotumumab, New Era for Thyroid Eye Disease

open access: yes, 2022
Thyroid eye disease is a progression of an autoimmune disease called Graves disease, which majorly affects eye orbits and its muscular tissues. It affects the patients by acting a impact on their quality of life by acting on patients visual balance along
Kale Rohit, Shrikant Solnake*
core   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

open access: yes, 2022
Hepatology, EarlyView.
Robert J. Fontana   +6 more
wiley   +1 more source

Early Clinical and Cerebrospinal Fluid Predictors of 1‐Year Recurrence in Autoimmune GFAP Astrocytopathy

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Autoimmune glial fibrillary acidic protein astrocytopathy (GFAP‐A) is an inflammatory central nervous system disorder with variable outcomes. Relapse occurs in a subset of patients, but early predictors remain unclear. We aimed to identify admission‐available features associated with 1‐year recurrence and develop an interpretable ...
Qingting Hong   +10 more
wiley   +1 more source

Survival Outcomes in Older Adults With Axial Spondyloarthritis and Concomitant Cancer

open access: yesArthritis Care &Research, EarlyView.
Objective The objective of this study was to determine survival outcomes in older adults with axial spondyloarthritis (axSpA) and concomitant cancer. Methods We conducted a population‐based study using Medicare claims data linked to Surveillance, Epidemiology, and End Results data to determine overall survival (OS) and cancer‐specific survival (CSS) in
Savannah Bowman   +7 more
wiley   +1 more source

Jod-Basedow phenomenon: Reactivation of thyroid eye disease after contrast computed tomography

open access: yesAfrican Vision and Eye Health, 2018
To report a case of Jod-Basedow phenomenon, where a patient with quiescent thyroid eye disease became active after a contrast computed tomography (CT).
Roland Hollhumer, Francesca Indiveri
doaj   +1 more source

Thyroid eye disease: Etiopathogenesis and management

open access: yesTNOA Journal of Ophthalmic Science and Research, 2022
Thyroid eye disease has been a well-recognized clinical entity related to thyroid gland dysfunction for more than a century. However, the last couple of decades devoted to specific clinical research regarding this entity has significantly contributed to ...
G Seethapathy, V G Madanagopalan
doaj   +1 more source

Thyroid Eye Disease

open access: yes, 2021
Dr.
Andrew G. Lee, MD; Zainub Abdullah
core  

A Holistic Platform Approach for Developing Robust Pulmonary mRNA Delivery: Integrating Novel Phenolic Acid‐Derived Ionizable Lipids and Device Engineering

open access: yesAdvanced Functional Materials, EarlyView.
An integrated pulmonary mRNA delivery platform combining novel biodegradable syringic acid‐derived ionizable lipids, design‐of‐experiments formulation optimization, and vibrating‐mesh nebulizer engineering enabled stable aerosolization and efficient lung delivery.
Neha Kaushal   +21 more
wiley   +1 more source

Home - About - Disclaimer - Privacy